KNOXVILLE, TN, UNITED STATES, January 8, 2026 /EINPresswire.com/ -- Daisy Genomics Inc. (“Daisy Genomics”) and New Day ...

Dublin, Jan. 16, 2018 (GLOBE NEWSWIRE) -- The "Global Liquid Biopsy Market Outlook to 2023" report has been added to ResearchAndMarkets.com's offering. The global liquid biopsy market is projected to ...

Advances in next-generation sequencing (NGS) and synthetic DNA technologies are reshaping oncology research by enabling earlier cancer detection, more accurate biomarker discovery, and sensitive ...

Scientists increasingly appreciate the importance of molecular testing for early cancer detection. 1 Cell free DNA (cfDNA) analysis eliminates the need for invasive tissue biopsies for detection, ...

Tal Parnes, Chairman of the Board of Inspira Technologies, stated: “The contemplated acquisition of this liquid biopsy platform represents a significant value inflection point for Inspira, adding a ...

The promise of scientific and medical innovation often comes with a downside: improvements in care benefit some people, but not all. Without concerted effort, that is exactly what could happen with ...

Cell-free DNA (cfDNA) library preparation is fundamental for successful and efficient next-generation sequencing (NGS) workflows. Researchers apply these techniques to a wide range of platforms, ...

Cancer is no longer considered untreatable, yet improving the accuracy and timeliness of diagnostics and treatment remains ...

"In our study, we showed that fine needle aspiration (FNA) biopsy material can be a good source for next-generation sequencing (NGS) for patients with metastatic prostate cancer. Based on these ...